Lexaria Begins Dosing in Oral Semaglutide Study vs. Wegovy

Lexaria Bioscience Corp. (Nasdaq: LEXX) has begun dosing in its Human Pilot Study #7 (GLP-1-H26-7) on June 14th, evaluating two oral DehydraTECH-semaglutide (DHT-sema) compositions against Novo Nordisk's Wegovy® tablets over five weeks. The study aims to preserve the superior safety and tolerability seen in previous GLP-1 studies like Human Study #4, while achieving pharmacokinetic performance matching or exceeding Wegovy®. Prior single-dose studies, such as GLP-1-H24-1 and GLP-1-H24-2, demonstrated PK performance matching or exceeding Rybelsus® with strong safety profiles. The pharmaceutical industry is expected to review these results carefully for potential commercial relationships.

The study includes three arms comparing SNAC-inclusive DHT-sema formulations in tablets and capsules to Wegovy® tablets under fasted conditions. A five-week dosing period allows achievement of steady state concentration levels, where drug input balances elimination. Key innovations include the first use of an oral DHT-sema tablet, mimicking properties of Rybelsus® and Wegovy® tablets to enhance absorption and align with industry standards. Additionally, both tablet and capsule formulations include SNAC, evaluated for the first time over multiple doses and weeks, building on single-dose studies from 2024-2025.

The study is fully funded from existing resources. Lexaria's DehydraTECH™ platform improves oral drug delivery, increasing bio-absorption and reducing side effects. The company holds 66 patents globally and operates a licensed research lab. Results could pave the way for licensing deals, offering a potentially safer oral GLP-1 alternative with fewer side effects than current injections.